2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P5345
    KLA peptide 184240-26-4 98%
    KLA peptide is a naturally occurring Antibiotic peptide that is nontoxic outside of cells but is toxic when it enters into the interior of targeted cells. KLA peptide can induce cell Apoptosis by disrupting mitochondrial membranes and activating Caspase. MG1-KLA, formed by the coupling of KLA peptide with MG1, can selectively induce apoptosis in pro-inflammatory microglia. KLA peptide can be used for the research of liver fibrosis. KLA peptide can be used for the research of neonatal hypoxic-ischemic encephalopathy.
    KLA peptide
  • HY-P5523
    iE-DAP 592520-07-5 98%
    iE-DAP is a Nod1 agonist. iE-DAP activates NOD1, which in turn activates the NF-κB signaling pathway and MLCK signaling pathway, inducing cellular inflammatory responses and tight junction disruption. iE-DAP downregulates the expression of ZO-1 and Occludin genes. iE-DAP increases the secretion of IL-6, GRO-α, MCP-1, IL-8 and MIP-1β in term human trophoblast cell cultures. iE-DAP triggers preterm birth in pregnant mice, reduces fetal body weight, and induces fetal inflammation. iE-DAP is applicable to research related to mastitis and preterm birth.
    iE-DAP
  • HY-P5578
    A8SGLP-1 753024-08-7 98%
    A8SGLP-1 is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 reduces blood glucose in db/db mice without affecting its function.
    A8SGLP-1
  • HY-P5878
    RG33 Peptide 98%
    RG33 Peptide is a diabetes inhibitor that significantly improves glucose clearance in insulin-resistant mice. RG33 Peptide effectively solubilizes lipid vesicles and promotes cholesterol efflux in cultured macrophages. RG33 Peptide is used in research into type 2 diabetes (T2D).
    RG33 Peptide
  • HY-P5897
    GnRH antagonist 3 292141-31-2 98%
    GnRH antagonist 3 (Compound 11) is a GnRH antagonist with an IC50 of 7 nM. GnRH antagonist 3 can be used in the research of hormone-dependent diseases.
    GnRH antagonist 3
  • HY-P6176
    JLB2-110c 3032608-72-0 98%
    JLB2-110c activates MCRs receptor (mMC4R EC50 = 0.34 nM) and has a strong in vivo appetite suppressant effect.
    JLB2-110c
  • HY-Z0437
    Dapagliflozin methyl acetate 1632287-34-3
    Dapagliflozin methyl acetate is an orally active SGLT2 inhibitor. Dapagliflozin methyl acetate may be used in type 2 diabetes research.
    Dapagliflozin methyl acetate
  • HY-Z1764
    DPP-4-IN-18 486460-31-5 98%
    DPP-4-IN-18 (Sitagliptin impurity 3) (Compound 4) impurity 3 is a potent, selective and orally active DPP-4 inhibitor with an IC50 of 27 nM. DPP-4-IN-18 can effectively prevent DPP-4 from degrading glucagon-like peptide 1 (GLP-1), thereby increasing the level of active GLP-1. DPP-4-IN-18 can be used for the research of type 2 diabetes.
    DPP-4-IN-18
  • HY-Z7760
    Felodipine 3,5-dimethyl ester 91189-59-2 98%
    Felodipine 3,5-Dimethyl Ester is a aryldihydropyridine derivatives for use as mineralocorticoid receptor modulator and voltage-dependent L-type calcium channel CaV1.2 inhibitor.
    Felodipine 3,5-dimethyl ester
  • HY-10003A
    1α-Hydroxy-3-epi-vitamin D3 58028-00-5 99.30%
    1α-Hydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone (PTH) secretion.
    1α-Hydroxy-3-epi-vitamin D3
  • HY-10003S
    Alfacalcidol-d7 98%
    Alfacalcidol-d7 is the deuterium labeled Alfacalcidol. Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis.
    Alfacalcidol-d7
  • HY-100120
    Pparδ agonist 2 870884-12-1 98%
    Pparδ agonist 2 is a PPARδ agonist extracted from patent WO 2016057656 A1.
    Pparδ agonist 2
  • HY-100127
    ML247 1222374-44-8 98%
    ML247 is a non-inhibitory and selective small molecule chaperone of acid alpha glucosidase. ML247 can be used for the research of metabolic disease, such as Pompe disease.
    ML247
  • HY-100189
    LS2265 72678-30-9 98%
    LS2265 is a taurine derivative of fenofibrate and can induce proliferation of peroxisomes in liver cells of rats.
    LS2265
  • HY-100193
    FK-448 Free base 85858-76-0 98%
    FK-448 Free base is an effective and specific inhibitor of chymotrypsin, with an IC50 of 720 nM.
    FK-448 Free base
  • HY-100299
    RPR107393 free base 197576-78-6 98%
    RPR107393 free base is an orally active potent selective squalene synthase (SQS) inhibitor. RPR107393 free base inhibits rat liver microsomal squalene synthase with an IC50 value of 0.8 nM. RPR107393 free base reduces triglyceride biosynthesis by suppressing fatty acid biosynthesis via an increase in intracellular farnesol and its derivatives. RPR107393 free base reduces plasma cholesterol in rats and marmosets. RPR107393 free base can be used for metabolic disease research, such as hypercholesterolemia, hypertriglyceridemia and atherosclerosis[1][2].
    RPR107393 free base
  • HY-100313
    YM-53601 free base 182959-28-0 98%
    YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo. YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent. YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation.
    YM-53601 free base
  • HY-100319
    UK-157147 162704-20-3 98%
    UK-157147 is a substrate for UDP-glucuronosyltransferases (UGT1A1) with a Km value of 105 μM.
    UK-157147
  • HY-100327
    MK-6913 1398510-92-3 98%
    MK-6913 (Tetrahydrofluoroene 52) is a potent and selective estrogen receptor β agonist.
    MK-6913
  • HY-10042S
    Odanacatib-d4 98%
    Odanacatib-d4 is the deuterium labeled Odanacatib (HY-10042). Odanacatib is a potent and selective inhibitor of cathepsin K, with an IC50 of 0.2 nM for human cathepsin K.
    Odanacatib-d4
Cat. No. Product Name / Synonyms Application Reactivity